Structure Therapeutics Inc American Depositary Shares

Yahoo Finance • 3 days ago

Here is Why Structure Therapeutics (GPCR) is One of the Top Biotech Names to Look at

Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the 10 best biotech stocks with highest upside potential. As of April 24 closing, the stock carries a strongly bullish consensus sentiment, receiving Buy ratings from all 14 analysts. Ba... Full story

Yahoo Finance • 24 days ago

Guggenheim Remains Bullish on Eli Lilly (LLY) Ahead of Q1 2026 Results

Eli Lilly and Company (NYSE:LLY) is included in our list of the 14 hedge fund favorites with strong setup in 2026.Guggenheim Remains Bullish on Eli Lilly (LLY) Ahead of Q1 2026 Results On March 30, 2026, Guggenheim updated its model ahead... Full story

Yahoo Finance • last month

These 5 Biotechs Could Be the Next Big GLP-1 Acquisition Target

Quick Read The GLP-1 wave has triggered a broader biopharma M&A cycle extending well beyond obesity drugs. These five biotech companies represent compelling acquisition targets, ranging from pure-play GLP-1 developers to adjacent pipeline... Full story

Yahoo Finance • last month

Structure Therapeutics Slides 28% This Year as $6 Million Stake Emerges

On February 17, 2026, B Group, Inc. disclosed a new position in Structure Therapeutics(NASDAQ:GPCR), acquiring 90,000 shares in the fourth quarter. What happened B Group disclosed in a Securities and Exchange Commission (SEC) filing date... Full story

Yahoo Finance • last month

Eli Lilly Confirms 'Superior Weight Loss' Of Its Next-Generation Obesity Drug

Eli Lilly reported study results Thursday that confirmed the "superior weight loss profile" of its next-gen obesity drug, retatrutide. Continue Reading... Full story

Yahoo Finance • last month

Eli Lilly's Experimental Drug Retatrutide Delivers Strong Weight Loss In Late-Stage Trial

Eli Lilly reported its experimental drug retatrutide delivered stronger weight loss than current treatments. Continue Reading... Full story

Yahoo Finance • 2 months ago

Structure Therapeutics Pops; But Can It Take On Lilly's Looming Obesity Pill?

Structure Therapeutics shares surged Monday after the biotech said its daily pill helped patients lose up to 39 pounds over a 44-week study. Continue Reading... Full story

Yahoo Finance • 2 months ago

Structure Therapeutics rises on mid-stage data for oral GLP-1

[A GLP-1 pill isolated on white background] zimmytws/iStock via Getty Images * Structure Therapeutics (GPCR [https://seekingalpha.com/symbol/GPCR]) is ~8% in Monday trading after reporting promising topline phase 2 data on its oral GLP-... Full story

Yahoo Finance • 2 months ago

Structure Therapeutics (GPCR) Gained from Favorable Clinical Data

Meridian Funds, managed by ArrowMark Partners, released its fourth-quarter 2025 investor letter for “Meridian Small Cap Growth Fund”. A copy of the letter can be downloaded here. U.S. equity markets navigated a quarter supported by optimis... Full story

Yahoo Finance • 3 months ago

This Healthcare Company Believes Its GLP-1 Pill Could Be "Next in Line" After Novo Nordisk and Eli Lilly. Its Valuation Is a Fraction of Theirs.

Novo Nordisk and Eli Lilly are the two leading companies in the GLP-1 drug race right now. But the field is inevitably going to get bigger as more drugmakers are researching obesity drugs in the hopes of securing some significant market sh... Full story

Yahoo Finance • 3 months ago

Obesity stocks slump on Novo's underwhelming 2026 sales forecast

Feb 3 (Reuters) - Shares of obesity drugmakers and developers slid on Tuesday after Novo ​Nordisk forecast a sharper-than-expected sales decline ‌for 2026, underscoring intensifying competition in the blockbuster weight-loss market. Eli ‌... Full story

Yahoo Finance • 4 months ago

Stocks making the biggest moves midday: Novo Nordisk, ServiceNow, Freeport-McMoRan, Structure Therapeutics & more

Check out the companies making headlines in midday trading. ServiceNow — Shares of the software company fell nearly 3% after it said it would acquire cybersecurity startup Armis for $7.75 billion . The deal, which should close next year, w... Full story

Yahoo Finance • 5 months ago

Eli Lilly Puts Obesity Field 'On Notice' With Best-Ever Weight Loss

Eli Lilly is putting the "obesity field on notice again," an analyst said Thursday after its next-gen delivered 28.7% weight loss. Continue Reading... Full story

Yahoo Finance • 5 months ago

Eli Lilly's Experimental Obesity Drug Cut Weight By 23.7%

Eli Lily rose above a key level after saying its experimental obesity treatment delivered 23.7% weight loss in a late-stage trial. Continue Reading... Full story

Yahoo Finance • 5 months ago

Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants

SAN FRANCISCO, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obes... Full story

Yahoo Finance • 5 months ago

In The 'Uber Bull' Biotech Market, Is Structure The Next Metsera?

In a post-Metsera world, Structure Therapeutics could be the next big takeover candidate, analysts said Tuesday. Continue Reading... Full story

Yahoo Finance • 5 months ago

Structure Therapeutics Announces Proposed $500 Million Public Offering of American Depositary Shares and Pre-Funded Warrants

SAN FRANCISCO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obes... Full story

Yahoo Finance • 5 months ago

Structure Therapeutics Soars; CEO Says It Could Have 'Best-In-Class' Weight-Loss Drug

Structure Therapeutics said Monday patients who took its obesity treatment lost up to 15.3% more body weight than placebo recipients. Continue Reading... Full story

Yahoo Finance • 5 months ago

Structure Therapeutics Reports Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

Structure Therapeutics Inc. Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight loss up to... Full story

Yahoo Finance • 5 months ago

Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025

SAN FRANCISCO, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obes... Full story